Canada, China team up on vaccine candidate
2020-05-15 00:00
The National Research Council of Canada is collaborating with Chinas CanSino Biologics Inc to advance the bioprocessing and clinical development in Canada of a vaccine candidate against COVID. The collaboration on the vaccine candidate, AdnCoV, was announced on Tuesday. AdnCoV received Chinese regulatory approval in March, allowing CanSino Biologics to move ahead with human clinical trials in China. It is one of only a handful of COVID vaccine candidates in the world approved for initial safety testing on humans, and was the first to begin conducting phasetwo human clinical trials, according to a statement released by the NRC.                                                                                                                                                                                                                                                                           !CDATA            function shareweixin              var ua  navigator.userAgent.toLowerCase              ifiphoneipadipod.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyiosschemeencodeIos                            else ifandroid.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyandroidschemeencodeAndroid                            else                window.openwww.chinadaily.com.cnmobiledaily.html